MAY-20-13 Dr. Ronald Valdiserri writes to recognize the second anniversary of Combating the
Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care
& Treatment of Viral Hepatitis and to share
an important announcement from Dr. Howard Koh about plans to update and renew the
existing plan through
MAY-16-13 Dr. Howard Koh, the Assistant Secretary for Health, announced on May 16 that the partner agencies are committed and dedicated to renewing the Action Plan for another three years and are currently working on their vision and priorities for 2014-2016.
|Forum HCV Drug Resistance Slideset (ResisSS 2012 V.2)|
Given the rapid pace of HCV drug development, the Forum's ResisSS has been updated and revised into four subsets:
1. HCV Lifecycle, Drug Targets, and Mechanisms of Action | PPT | PDF |
Along with incorporating recent data from AASLD 2012, the #3 Treatment Strategies set has been subdivided into interferon-containing and interferon-free regimens.
Recognizing the need for HCV drug resistance education, the members of
the Forum for Collaborative HIV Research's HCV Drug Development Advisory
Group (academicians, clinicians, researchers and patient advocates)
have contributed to a slide deck explaining drug resistance in HCV, its
consequences, as well as mitigating its impact.
The educational slide deck’s intended audience ranges the spectrum from health care providers evaluating, diagnosing and treating HCV, patients who want to learn about the disease and treatment options, and advocates who may use the slides in their community education outreach efforts.
These slides may be used in the user's own noncommercial presentations, but kindly do not change content and attribution. We also ask that the slides not be published or posted online without permission from the Forum for Collaborative HIV Research.
For comments or more information, please contact Erik Lontok (email@example.com)